Online citations, reference lists, and bibliographies.

Osteosarcoma: The European Osteosarcoma Intergroup (EOI) Perspective.

A. Craft
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
In the late 1970s, there was confusion regarding the best management for osteosarcoma. The benefit of chemotherapy had not been established and which chemotherapy could be used was even more uncertain. The European Osteosarcoma Intergroup (EOI) was established in order to conduct randomised studies to determine the best treatment for this tumour. Their first study 80831 established that a two drug combination of CDDP/DOX was safe and improved the survival rate over previous regimes with suboptimal chemotherapy. The CDDP/DOX was superior to a less intense CDDP/DOX/MTX regime. The second study 80861 compared the CDDP/DOX arm with a multi-drug Rosen-T10 regime. In almost 400 patients, there was the difference in outcome between the two arms. However, adherence to the protocol and completion of allocated treatment was substantially less good in the prolonged 42 week multi-drug regime compared to the two drug arm. The third study 80961 investigated interval compression i.e. if the CDDP/DOX when given every 2 weeks with GCSF superior to the same two drugs given every 3 weeks. There was no difference in survival between the arms, although there was a better histologic response rate in the compressed arm. Three randomised controlled trials on this rare disease have taken more than 20 years to accrue a sufficient sample of patients. The overall outcome has changed little in this time. Large multinational studies are needed to be able to answer these important questions in a timely fashion.
This paper references
10.1200/JCO.1987.5.1.21
Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial.
F. Eilber (1987)
10.1002/1097-0142(19820315)49:6<1221::AID-CNCR2820490625>3.0.CO;2-E
Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy
G. Rosen (1982)
10.1016/S0140-6736(97)02307-6
Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup
R. Souhami (1997)
10.1007/978-4-431-68072-7_18
European Osteosarcoma Intergroup
J. W. Eijken (1989)
10.1200/JCO.1994.12.9.1842
Doxorubicin and cisplatin with granulocyte colony-stimulating factor as adjuvant chemotherapy for osteosarcoma: phase II trial of the European Osteosarcoma Intergroup.
D. Ornadel (1994)
High-dose methotrexate in osteogenic sarcoma: a 5-year experience.
N. Jaffe (1978)
10.1056/NEJM198606193142502
The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity.
M. Link (1986)
Chemotherapy for osteogenic sarcoma: an investigative method, not a recipe.
G. Rosen (1982)
10.1200/JCO.1992.10.10.1579
A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup.
V. Bramwell (1992)
10.1002/1097-0142(19880301)61:5<1024::AID-CNCR2820610528>3.0.CO;2-P
Osteosarcoma of the limbs. Report of the EORTC‐SIOP 03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation
J. M. V. Burgers (1988)
10.1200/jco.1984.2.3.152
A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma.
J. Edmonson (1984)
10.1002/jso.2930040512
The therapy of osteogenic sarcoma: Current status and thoughts for the future
M. Friedman (1972)
10.1200/JCO.2000.18.24.4028
Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup.
I. Lewis (2000)
10.1093/JNCI/DJK015
Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.
I. Lewis (2007)



This paper is referenced by
10.1515/hsz-2018-0292
SIAH1/ZEB1/IL-6 axis is involved in doxorubicin (Dox) resistance of osteosarcoma cells
Xiuxin Han (2019)
10.1302/0301-620X.98B6.37417
Very long-term outcomes after endoprosthetic replacement for malignant tumours of bone.
R. Grimer (2016)
10.1016/B978-0-323-03329-9.50025-8
Malignant Tumors of Bone
R. Heck (2008)
10.1097/MPH.0000000000000802
ATIC Gene Polymorphism and Histologic Response to Chemotherapy in Pediatric Osteosarcoma
Jeong Ah Park (2017)
10.1097/MD.0000000000021311
Neuromuscular electrical stimulation for cancer pain in children with osteosarcoma
T. Wang (2020)
10.1097/MPH.0000000000001407
Pediatric Osteosarcoma of Extremities: A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt
A. M. Morsy (2019)
Time to relapse predicts post-relapse survival in recurrent osteosarcoma : a meta-analysis
J. Mao (2016)
10.1186/s13018-020-1576-0
The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis
B. Zhang (2020)
10.1007/978-3-319-04843-7_1
Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma.
N. Jaffe (2014)
Her-2 / ErbB2 expression is not a prognostic factor in high-grade osteosarcoma : a systematic review and meta-analysis
J. Mao (2018)
10.1097/MPH.0000000000001506
Age and Tumor Location Predict Survival in Nonmetastatic Osteosarcoma in Upper Egypt
Ahmed Mohammed Morsy (2019)
10.1080/15384047.2019.1591675
Visfatin is involved in the cisplatin resistance of osteosarcoma cells via upregulation of Snail and Zeb1
D. Wang (2019)
10.1016/j.clinthera.2014.02.018
Analysis of chemotherapy dosage and dosage intensity and survival outcomes of high-grade osteosarcoma patients younger than 40 years.
Lingling Sun (2014)
Semantic Scholar Logo Some data provided by SemanticScholar